European Anagrelide Cancer Patent
Filed with ASX · · 2 pages · English
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Supplementary Prospectus
- Rights Issue Closes Significantly Oversubscribed
- SUDA SIgns Binding Term Sheet With Cann Pharmaceutical
- Prospectus For Renounceable Pro Rata Offer
- Rights Issue To Raise Up To $3.44 Million
Later from Arovella Therapeutics
- ZolpiMist Clinical Results Published
- ArTiMist Appeal Lodged With TGA
- Manaing Director and CEO Resignation
- Response to ASX Query regarding Accounts
- SUDA Finalises Agreement With Cann Pharmaceutical
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics